The study included 15 pediatric patients with at least three episodes of C. difficile within a three-month period. Patient follow-up was conducted via phone 24 hours and one week after the procedure. Patients were told to see their gastroenterologist at one and three months post-procedure.
Here are four findings:
1. The study found that 14 out of 15 patients reported no additional episodes more than three months following the procedure.
2. Three patients were hospitalized a month after the procedure for diarrhea, dehydration and rCDI.
3. Only one patient was found to actually have clinical symptoms of C. difficile plus a positive stool test.
4. The study is limited, however, due to the small sample size, among other factors.
More articles on GI/endoscopy:
Mederi Therapeutics launches 3rd generation of Stretta, Boston Scientific reports Q1 2016 financials & more — 5 GI company key notes
Gastroenterologist pay in the US, UK, Canada & Australia: 5 notes
Seres Therapeutics signs research agreements to support development of microbiome therapy for IBD: 3 points
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.